Genetic reports abstractBrief communicationAnalysis of C9orf72 repeat expansion in 563 Japanese patients with amyotrophic lateral sclerosis
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that primarily affects motor neurons in the spinal cord, brain stem, and cerebral cortex, typically leading to death within a few years. Five to ten percent of ALS cases are familial, and the remaining cases are believed to be sporadic (Valdmanis et al., 2009). A number of genes causing ALS with a dominant mode of inheritance have been discovered, such as SOD1, TARDBP, FUS, VAPB, ANG, VCP, OPTN (Ticozzi et al., 2011), and UBQLN2 (Deng et al., 2011). Moreover, there is increasing clinical and pathological evidence for the hypothesis that ALS and frontotemporal dementia (FTD) constitute an overlapping continuum of diseases (Lomen-Hoerth et al., 2002, Neumann et al., 2006). Recently, the expansion of a noncoding GGGGCC hexanucleotide repeat in the C9orf72 gene has been reported to be a major cause of both ALS and FTD (DeJesus-Hernandez et al., 2011, Gijselinck et al., 2012, Renton et al., 2011) and the most common genetic abnormality in familial and sporadic forms of both ALS and FTD, particularly in Western populations (Chiò et al., 2012, DeJesus-Hernandez et al., 2011, Gijselinck et al., 2012, Renton et al., 2011; Sabatelli et al., 2012; Stewart et al., 2012). In the present study, we describe the incidence and demographic and clinical features associated with the C9orf72 mutation in a large cohort of Japanese ALS patients. We also perform haplotype analysis to investigate whether Japanese patients have the same risk haplotype as European patients (Gijselinck et al., 2012, Laaksovirta et al., 2010, Mok et al., 2012).
Section snippets
Subjects
We obtained a total of 760 DNA samples from the Japanese Consortium for Amyotrophic Lateral Sclerosis Research (JaCALS; Appendix A). A total of 563 (11 familial and 552 sporadic) patients were diagnosed with ALS according to the El Escorial revised criteria (Brooks et al., 2000) and classified as bulbar-onset, spinal-onset, FTD-ALS, or other (see Supplementary Table 1 for details). We had determined the family histories of ALS but not FTD or primary progressive aphasia (PPA) in all of the
Detection of C9orf72 repeat expansion
The C9orf72 repeat expansion was found in 2 of 522 Japanese patients (2/552 = 0.4%) with SALS and none of the 11 patients (0/11 = 0%) with familial ALS (FALS) using repeat-primed PCR (Table 1). Patient A-I with a C9orf72 mutation was classified as SALS in this study, but after detecting the mutation, we found that patient A-II (a brother of patient A-I) developed aphasia and dementia and had a C9orf72 mutation (Fig. 1). The average repeat number based on fluorescent fragment-length analysis was
Discussion
We began this study considering patients without family histories of ALS to be SALS because our cohort included only family histories of ALS but not FTD or PPA. Although it may be difficult to describe the real frequency in SALS because 1 of the SALS patients had a family member who developed PPA, the frequencies of the C9orf72 mutation in Japanese patients were 0.4% (2/552) in SALS and 0% (0/11) in FALS according to this classification. In contrast, the frequencies of the C9orf72 mutation fall
Disclosure statement
All of the authors disclose no conflicts of interest. The study was approved by the ethical committees of the participating centers. All participants gave written informed consent.
Acknowledgements
The authors thank all of the participants in this study. The authors also thank Dr. Mariely DeJesus-Hernandez, Dr. Ilse Gijselinck, Dr. Marc Cruts, and Dr. Christine Van Broeckhoven for technical advice. This work was supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan (21229011, 21390272, 21591098, 22790817, 22790829, and 23659452), the Ministry of Welfare, Health and Labor of Japan (20261501, 22140501, 22140901, and CCT-B-1701), the Japan Science and
References (20)
- et al.
Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study
Lancet Neurol
(2012) - et al.
Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS
Neuron
(2011) - et al.
A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study
Lancet Neurol
(2012) - et al.
Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study
Lancet Neurol
(2010) - et al.
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study
Lancet Neurol
(2012) - et al.
A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD
Neuron
(2011) - et al.
High-Resolution Melting (HRM) Analysis of the Cu/Zn Superoxide Dismutase (SOD1) Gene in Japanese Sporadic Amyotrophic Lateral Sclerosis (SALS) Patients
Neurol. Res. Int
(2011) - et al.
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
Amyotroph. Lateral Scler. Other Mot. Neuron Disord
(2000) - et al.
Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72
Brain
(2012) - et al.
Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72
Brain
(2012)
Cited by (99)
Parkinsonism and motor neuron disorders: Lessons from Western Pacific ALS/PDC
2022, Journal of the Neurological SciencesMutation screening of SLC52A3, C19orf12, and TARDBP in Iranian ALS patients
2019, Neurobiology of AgingCitation Excerpt :The disease-causing hexanucleotide repeat expansion in this gene was reported as the cause of ALS in approximately 40% and 20%, respectively, of Finish FALS and SALS patients (Renton et al., 2011). Although the mutation was also frequent in various populations of European descent, its contribution to ALS in Asian populations was much lower (0%–2%) (Jang et al., 2013; Ogaki et al., 2012; Tsai et al., 2012). With the exception of a recent important large-scale screening of ALS patients from Turkey, Iranian patients have constituted the only ALS cohort from the Middle East that have been genetically screened (Alavi et al., 2013, 2014; Ozoguz et al., 2015).